Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3
Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsmonoclonal_antibodyPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
587 Active assets in the Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Amsacrine University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-Vincristine Janssen Research & Development, LLC | Phase 3 | BBB |
Aclacinomycin Chinese PLA General Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →